The FDA has proposed a new system for approving customized drugs and therapies for rare diseases, which could provide hope for patients with conditions that are currently unprofitable for pharmaceutical companies to treat.
According to Associated Press, the FDA’s proposal could provide a new pathway for bespoke therapies that have only been tested in a handful of patients due to the challenges of conducting larger studies. The FDA announcement specifically mentions gene editing, although agency officials said the new approach could also be used by other drugs and therapies.
The proposal is a shift long sought by patients, advocates, and researchers focused on rare diseases, which often do not fit within the pharmaceutical industry’s business model or the FDA’s traditional drug-approval system. As stated by FDA Commissioner Marty Makary, “It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases.”
The announcement comes a week after Makary said the FDA would drop its decades-old standard of requiring two clinical trials for standard drug reviews. This is the latest in a series of changes to FDA norms and standards, many of which have not gone through federal procedures traditionally used to update agency rules.
What Does This Mean for Patients with Rare Diseases?
The new pathway, if implemented, could provide hope for patients with conditions that are currently unprofitable for pharmaceutical companies to treat. Traditionally, the FDA requires drugmakers to demonstrate the safety and effectiveness of their experimental treatments in clinical studies that compare a set of patients getting the therapy with others taking a sham treatment or an alternative intervention. However, for conditions that can affect a tiny fraction of people worldwide, drug companies often have little incentive to invest millions of dollars needed to complete a study and bring it through the FDA approval process, which can take a decade or longer.
The pathway announced Monday would create a standardized process for authorizing experimental treatments and, importantly, offering companies the possibility of commercializing them. The FDA already authorizes the use of experimental drugs under what’s called “compassionate use,” for people with no other medical options. But the process is cumbersome to navigate and strictly prohibits companies or researchers from profiting from treatments that haven’t been vetted by the FDA.
Conclusion
In conclusion, the FDA’s proposal for a new system for approving customized drugs and therapies for rare diseases is a significant step forward for patients with conditions that are currently unprofitable for pharmaceutical companies to treat. While there are still many challenges to overcome, this new pathway could provide hope for those who have been waiting for a treatment for their rare disease. For more information on this topic and other breaking news in the tech and science world, visit onlytrustedinfo.com, your trusted source for the fastest and most insightful analysis of breaking news.
